Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide

Chemical Research in Toxicology

Volumn 27, Issue 1, 2014, Pages 147-156

  Chowdhury, Goutam ^a   Shibata, Norio ^b   Yamazaki, Hiroshi ^c   Guengerich, F Peter ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

^c SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTHALIDOMIDE; CYTOCHROME P450; CYTOCHROME P450 2C18; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; CYTOCHROME P450 4A11; DRUG METABOLITE; PHTHALIMIDE; POMALIDOMIDE; QUINONE DERIVATIVE; THALIDOMIDE; UNCLASSIFIED DRUG; 5-HYDROXYTHALIDOMIDE;

ARTICLE; BIOTRANSFORMATION; COLLISIONALLY ACTIVATED DISSOCIATION; CONTROLLED STUDY; DRUG STRUCTURE; ENANTIOMER; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; INSECT CELL; LIVER MICROSOME; OXIDATION; PROTEIN EXPRESSION; TAUTOMER; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANALOGS AND DERIVATIVES; CHEMICAL STRUCTURE; CHEMISTRY; KINETICS; METABOLISM; OXIDATION REDUCTION REACTION;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; THALIDOMIDE;

EID: 84892899479     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx4004215     Document Type: Article

References (57)

1. Speirs, A. L. (1962) Thalidomide and congenital abnormalities Lancet 1, 303-305
2. Palumbo, A., Facon, T., Sonneveld, P., Blade, J., Offidani, M., Gay, F., Moreau, P., Waage, A., Spencer, A., Ludwig, H., Boccadoro, M., and Harousseau, J. L. (2008) Thalidomide for treatment of multiple myeloma: 10 years later Blood 111, 3968-3977
3. Zangari, M., Elice, F., and Tricot, G. (2005) Immunomodulatory drugs in multiple myeloma Expert Opin. Invest. Drugs 14, 1411-1418
4. Zhou, S., Wang, F., Hsieh, T. C., Wu, J. M., and Wu, E. (2013) Thalidomide-a notorious sedative to a wonder anticancer drug Curr. Med. Chem. 20, 4102-4108
5. Jabbour, E., Thomas, D., Kantarjian, H., Zhou, L., Pierce, S., Cortes, J., and Verstovsek, S. (2011) Comparison of thalidomide and lenalidomide as therapy for myelofibrosis Blood 118, 899-902
6. Barkin, J. A., Schonfeld, W. B., and Deshpande, A. R. (2013) Successful use of thalidomide for refractory esophageal Crohn's disease Am. J. Gastroenterol. 108, 855-857
7. Zhu, Y. X., Kortuem, K. M., and Stewart, A. K. (2013) Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma Leuk. Lymphoma 54, 683-687
8. Terpos, E., Kanellias, N., Christoulas, D., Kastritis, E., and Dimopoulos, M. A. (2013) Pomalidomide: A novel drug to treat relapsed and refractory multiple myeloma OncoTargets Ther. 6, 531-538
9. Lacy, M. Q. and McCurdy, A. R. (2013) Pomalidomide Blood 122, 2305-2309
10. Eriksson, T., Bjorkman, S., Roth, B., and Hoglund, P. (2000) Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man J. Pharm. Pharmacol. 52, 807-817
11. Hoglund, P., Eriksson, T., and Bjorkman, S. (1998) A double-blind study of the sedative effects of the thalidomide enantiomers in humans J. Pharmacokinet. Biopharm. 26, 363-383
12. Reist, M., Carrupt, P. A., Francotte, E., and Testa, B. (1998) Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites Chem. Res. Toxicol. 11, 1521-1528
13. Fabro, S., Smith, R. L., and Williams, R. T. (1965) Thalidomide as a possible biological acylating agent Nature 208, 1208-1209
14. Parman, T., Wiley, M. J., and Wells, P. G. (1999) Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity Nat. Med. 5, 582-585
15. Gordon, G. B., Spielberg, S. P., Blake, D. A., and Balasubramanian, V. (1981) Thalidomide teratogenesis: Evidence for a toxic arene oxide metabolite Proc. Natl. Acad. Sci. U.S.A. 78, 2545-2548
16. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis Proc. Natl. Acad. Sci. U.S.A. 91, 4082-4085
17. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., and Handa, H. (2010) Identification of a primary target of thalidomide teratogenicity Science 327, 1345-1350
18. Braun, A. G., Harding, F. A., and Weinreb, S. L. (1986) Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450 Toxicol. Appl. Pharmacol. 82, 175-179
19. Bauer, K. S., Dixon, S. C., and Figg, W. D. (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species dependent Biochem. Pharmacol. 55, 1827-1834
20. Ando, Y., Fuse, E., and Figg, W. D. (2002) Thalidomide metabolism by the CYP2C subfamily Clin. Cancer Res. 8, 1964-1973
21. Lu, J., Helsby, N., Palmer, B. D., Tingle, M., Baguley, B. C., Kestell, P., and Ching, L. M. (2004) Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans J. Pharmacol. Exp. Ther. 310, 571-577
22. Chowdhury, G., Murayama, N., Okada, Y., Uno, Y., Shimizu, M., Guengerich, F. P., and Yamazaki, H. (2010) Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formulation of a glutathione conjugate Chem. Res. Toxicol. 23, 1018-1024
23. Yamazaki, H., Suemizu, H., Shimizu, M., Igaya, S., Shibata, N., Nakamura, M., Chowdhury, G., and Guengerich, F. P. (2012) In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK-NOG mice Chem. Res. Toxicol. 25, 274-276
24. Yamazaki, H., Suemizu, H., Igaya, S., Shimizu, M., Shibata, N., Nakamura, M., Chowdhury, G., and Guengerich, F. P. (2011) In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice Chem. Res. Toxicol. 24, 287-289
25. 14C]-lenalidomide following oral administration in healthy male subjects Cancer Chemother. Pharmacol. 69, 789-797
26. 14C]pomalidomide in humans following oral administration Cancer Chemother. Pharmacol. 71, 489-501
27. - (2005) Cytochrome P450: Structrue, Mechanism, and Biochemistry (Ortiz de Montellano, P. R., Ed.) 3 rd ed., KluwerAcademic/Plenum Publishers, New York.
28. Guengerich, F. P. (2005) Human cytochrome P450 enzymes, in Cytochrome P450: Structrue, Mechanism, and Biochemistry (Ortiz de Montellano, P. R., Ed.) 3 rd ed., pp 377-530, KluwerAcademic/Plenum Publishers, New York.
29. Wu, S., Moomaw, C. R., Tomer, K. B., Falck, J. R., and Zeldin, D. C. (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart J. Biol. Chem. 271, 3460-3468
30. Zaphiropoulos, P. G. (1997) Exon skipping and circular RNA formation in transcripts of the human cytochrome P-450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis Mol. Cell. Biol. 17, 2985-2993
31. Yengi, L. G., Xiang, O., Pan, J., Scatina, J., Kao, J., Ball, S. E., Fruncillo, R., Ferron, G. M., and Wolf, C. R. (2003) Quantitation of cytochrome P450 mRNA levels in human skin Anal. Biochem. 316, 103-110
32. Kitada, M. and Kamataki, T. (1994) Cytochrome P450 in human fetal liver: significance and fetal-specific expression Drug Metab. Rev. 26, 305-323
33. Lee, C. A., Neul, D., Clouser-Roche, A., Dalvie, D., Wester, M. R., Jiang, Y., Jones, J. P., 3rd, Freiwald, S., Zientek, M., and Totah, R. A. (2010) Identification of novel substrates for human cytochrome P450 2J2 Drug Metab. Dispos. 38, 347-356
34. Kinobe, R. T., Parkinson, O. T., Mitchell, D. J., and Gillam, E. M. (2005) P450 2C18 catalyzes the metabolic bioactivation of phenytoin Chem. Res. Toxicol. 18, 1868-1875
35. Node, K., Huo, Y., Ruan, X., Yang, B., Spiecker, M., Ley, K., Zeldin, D. C., and Liao, J. K. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids Science 285, 1276-1279
36. Wu, S., Chen, W., Murphy, E., Gabel, S., Tomer, K. B., Foley, J., Steenbergen, C., Falck, J. R., Moomaw, C. R., and Zeldin, D. C. (1997) Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes J. Biol. Chem. 272, 12551-12559
37. Zeldin, D. C., Moomaw, C. R., Jesse, N., Tomer, K. B., Beetham, J., Hammock, B. D., and Wu, S. (1996) Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway Arch. Biochem. Biophys. 330, 87-96
38. Capdevila, J. H., Falck, J. R., and Imig, J. D. (2007) Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension Kidney Int. 72, 683-689
39. Gaedigk, A., Baker, D. W., Totah, R. A., Gaedigk, R., Pearce, R. E., Vyhlidal, C. A., Zeldin, D. C., and Leeder, J. S. (2006) Variability of CYP2J2 expression in human fetal tissues J. Pharmacol. Exp. Ther. 319, 523-532
40. Nishimura, M., Yaguti, H., Yoshitsugu, H., Naito, S., and Satoh, T. (2003) Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR Yakugaku Zasshi 123, 369-375
41. Yamamoto, T., Shibata, N., Sukeguchi, D., Takashima, M., Nakamura, S., Toru, T., Matsunaga, N., Hara, H., Tanaka, M., Obata, T., and Sasaki, T. (2009) Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides Bioorg. Med. Chem. Lett. 19, 3973-3976
42. Guengerich, F. P. and Bartleson, C. J. (2007) Analysis and characterization of enzymes and nucleic acids, In Principles and Methods of Toxicology (Hayes, A. W., Ed.) 5 th ed., pp 1981-2048, CRC Press, Boca Raton, FL.
43. Parikh, A., Gillam, E. M. J., and Guengerich, F. P. (1997) Drug metabolism by Escherichia coli expressing human cytochromes P450 Nat. Biotechnol. 15, 784-788
44. Hanna, I. H., Teiber, J. F., Kokones, K. L., and Hollenberg, P. F. (1998) Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities Arch. Biochem. Biophys. 350, 324-332
45. Gainer, J. V., Bellamine, A., Dawson, E. P., Womble, K. E., Grant, S. W., Wang, Y., Cupples, L. A., Guo, C. Y., Demissie, S., O'Donnell, C. J., Brown, N. J., Waterman, M. R., and Capdevila, J. H. (2005) Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension Circulation 111, 63-69
46. Omura, T. and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature J. Biol. Chem. 239, 2370-2378
47. Dieckhaus, C. M., Fernandez-Metzler, C. L., King, R., Krolikowski, P. H., and Baillie, T. A. (2005) Negative ion tandem mass spectrometry for the detection of glutathione conjugates Chem. Res. Toxicol. 18, 630-638
48. Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G., and Monks, T. J. (2000) Role of quinones in toxicology Chem. Res. Toxicol. 13, 135-160
49. Kadlubar, F. F., Miller, J. A., and Miller, E. C. (1976) Hepatic metabolism of N -hydroxy- N -methyl-4-aminoazobenzene and other N -hydroxy arylamines to reactive sulfuric acid esters Cancer Res. 36, 2350-2359
50. Tsen, C. C. (1961) An improved spectrophtometric method for the determination of tocopherols using 4,7-diphenyl-1,10-phenanthroline Anal. Chem. 33, 849-851
51. Wang, K. and Guengerich, F. P. (2013) Reduction of aromatic amines and heterocyclic aromatic amines by human cytochrome P450 2S1 Chem. Res. Toxicol. 26, 993-1004
52. Stephens, T. D., Bunde, C. J. W., and Fillmore, B. J. (2000) Mechanism of action in thalidomide teratogenesis Biochem. Pharmacol. 59, 1489-1499
53. Hansen, J. M., Harris, K. K., Philbert, M. A., and Harris, C. (2002) Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb J. Pharmacol. Exp. Ther. 300, 768-776
54. Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., Oriowski, R. Z., and Stewart, A. K. (2013) Cereblon expression is required for the antimyeloma activity fo lenalidomide and pomalidomide Blood 118, 4771-4779
55. Chen, C., Wei, X., Rao, X., Wu, J., Yang, S., Chen, F., Ma, D., Zhou, J., Dackor, R. T., Zeldin, D. C., and Wang, D. W. (2011) Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth J. Pharmacol. Exp. Ther. 336, 344-355
56. Mahony, C., Erskine, L., Niven, J., Greig, N. H., Figg, W. D., and Vargesson, N. (2013) Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro Proc. Natl. Acad. Sci. U.S.A. 110, 12703-12708
57. Christian, M. S., Laskin, O. L., Sharper, V., Hoberman, A., Stirling, D. I., and Latriano, L. (2007) Evaluation of the developmental toxicity of lenalidomide in rabbits Birth Defects Res., Part B 80, 188-207